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ABSTRACT
The development of resistance to the different antibiotics by the majority of bacterial species of clinical
importance seems unavoidable. However, not all drugs have the same efﬁciency to select for resistance.
Large differences in the qualitative and quantitative consumption of antibiotics among countries are
known to exist and several authors have consistently reported the direct relationship between
consumption and selection of resistance for Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus
inﬂuenzae and Escherichia coli and b-lactams and macrolides use. In Spain, extensive surveillance started
in 1996, and the Willow (SAUCE) Project, to monitor and update resistance in respiratory pathogens and
to couple those data with data concerning national antibiotic consumption (IMS) from both a temporal
and geographical approach. Temporally, despite a continuous increase of 16% in quinolone
consumption from 1997 to 2001, basically due to the arrival of respiratory quinolones, levoﬂoxacin
and moxiﬂoxacin, a continuous linear increase in the resistance rates to ciproﬂoxacin in S. pneumoniae
was not observed. There also was an inverse correlation between provincial consumption of quinolones
and resistance to ciproﬂoxacin. Several hypotheses are proposed and discussed to explain these
apparent paradoxical observations, such as the replacement of ciproﬂoxacin by more potent
antipneumococcal quinolones, the possibility of an antibiotic pressure threshold, the inﬂuence of other
nonquinolone drugs on the expression of ciproﬂoxacin-resistance biological costs, and the inﬂuence of
changes in temporal or spatial prevalence of particular clones.
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INTRODUCTION
It is a commonplace to talk about the huge
contribution that antibiotics represent to man-
kind since their progressive discovery and use
during the brief period of the last 60–70 years.
Since then, and still today, viewed by many as
‘miracle drugs’ able to rescue in just a few days
people threatened by all kinds of life-threaten-
ing and feared infections, they have always
been accompanied by an indulgent and some-
times overenthusiastic judgement about their
effects and capabilities. The over optimistic
sentence pronounced in 1969 by the Surgeon
General of the United States, William H. Stew-
art, in the US Congress, announcing that it was
about time ‘to close the book on infectious
diseases’ [1], backed by the great number of
different antibiotics developed by then, is now-
adays a naive example of naivety and underes-
timation of the tremendous adaptive potential of
micro organisms.
Retrospectively, we can observe that the only
infections that have become ‘something of the
past’, at least in certain regions where there have
been the necessary resources to do it, have been
controlled mostly by vaccination (smallpox,
poliomyelitis) and by improvements in public
health programmes. It is also undeniable that
even though antibiotics represent an outstanding
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addition to the then nonexistent arsenal against
infections, most of the microorganisms targeted
have managed to countermeasure many of these
drugs. Reports of resistant isolates can almost
always be traced back to a very short time after
the introduction of a given antimicrobial, and this
has happened for all kinds of microorganisms,
regardless of their relative nonselectivity for
human ecological niches, e.g., Escherichia coli,
Campylobacter, and Salmonella, or high niche spe-
cialisation, e.g., Streptococcus pneumoniae, Strepto-
coccus pyogenes, Neisseria meningitides, Haemophilus
inﬂuenzae, and even the recent human immuno-
deﬁciency virus (HIV). Antimicrobials seem to
have a worryingly short-life span in evolutionary
terms.
This has been particularly true in many devel-
oped countries, where accessibility to health care
and medicines is not limited (with exceptions
depending on the local health system) and over-
use of antibiotics can occur. Therefore, the selec-
tion of resistant organisms, mostly respiratory,
urinary and nosocomial microorganisms, has
been highly effective.
The development of resistance to the different
antibiotics by the majority of bacterial species of
clinical importance seems unavoidable, occur-
ring in some instances as early as the ﬁrst few
years of antimicrobial use. The selective events
on which the development of resistance are
based, suggest that the more effective antibiotics
should be the more prone to act as selectors, if
speciﬁc mechanisms of resistance are available.
Indeed, not all drugs have the same efﬁciency
to select for resistance in a given bacterial
species, giving rise to a number of questions.
Is there any means to measure the relative
importance of different antibiotics in resistance
selection? What evidence enables us to put the
corresponding blame at least on each antibiotic
family?
This article intends to review critically the
information available on this topic as well as to
assess the inﬂuence of the consumption of quino-
lones on the prevalence of resistance of S. pneu-
moniae to ciproﬂoxacin through an ecological
study carried out in Spain. By no means does
this article intend to be a comprehensive review
of all the literature available on the topic, but only
of what we have considered relevant for our
purposes, and more speciﬁcally focusing on the
Spanish experience.
DIFFERENCES IN THE
CONSUMPTION OF
ANTIMICROBIALS AND IN THE
PATTERNS OF RESISTANCE
In Europe [2], there are huge differences in the
quantitative and qualitative aspects of antibiotic
consumption among countries. The pattern of
higher consumption in the South and East than in
the North, correlating with higher rates of resist-
ance where consumption was higher, have also
been observed [3].
Compared with other European countries,
Spain ranked second in antibiotic consumption
with 32.4 DID, very close to France with 36.5 DID;
Portugal and Belgium ranked third and fourth.
Holland and Denmark were at the opposite end
with only 8.9 and 11.3 DID, respectively, which
represents one-third of the French or Spanish
consumption [4].
The study by Cars et al. in 1997 not only
underlines the wide quantitative variation in the
total volume of consumption among countries,
but also the different qualitative patterns. Portu-
gal was the ﬁrst country to use quinolones,
followed by Belgium and Italy. Greece was the
ﬁrst to use cephalosporins, followed by France,
Portugal and Italy. As for the use of macrolides
and lincosamides, the rank order was France,
Spain, Italy, Luxembourg and Greece. To sum-
marise, ample quantitative and qualitative varia-
tions in the consumption of antibiotics are
observed among countries, and these differences
also exist on a different scale among different
regions of the same country [5,6]. However, this
information, when it exists, requires more de-
tailed data, and is usually very fragmented. These
differences in antibiotic consumption can be due
to differences in the national or regional health
and pharmaceutical policies, social, economical
and educational inequalities, differences in the
prevalence of the more common infectious epi-
sodes and in host-susceptibility to these infec-
tions, and even to commercial strategic factors,
climate and geographical conditions [5].
In Spain, it was estimated that the overall use of
antibiotics in deﬁned daily doses (DDD) ⁄ 1000
inhabitants ⁄day (DID) varied from 16.3 in 1987 to
20.6 in 1997, a 26% increase. Wide spectrum
penicillins (J1C group) represented more than half
of the total, although this proportion decreased
from 64% in 1987 to 56% in 1997, along with an
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8.6% increase in consumption (from 10.6 to 11.5
DID). Of note is the evolution of amoxicillin ⁄ cla-
vulanate usage from 1.3 DID (12.3% of J1C) in
1987 to 4 DID (34.8% of J1C) in 1997 (a 208%
increase). In contrast, macrolides (J1F), quinolones
(J1G) and cephalosporins (J1D) increased to 18%,
11% and 9% in 1997, with DID increases of 190%,
76% and 363%, respectively. Within the J1D
cephalosporin group, those of ﬁrst generation
(76% of J1C in 1987 vs. 4% in 1997) were
displaced by the second generation (22% in 1987
vs. 60% in 1997). As for macrolides (J1F), eryth-
romycin represented 75% of the group in 1987,
descending to 25% in 1997, this gap being
occupied by clarithromycin and azithromycin.
La´zaro-Bengoa et al. [7] employed the same
database mentioned above although with addi-
tional consumption data covering the period from
1985 to 2000 (thus, overlapping the 1987 and 1997
period), and providing nonaggregated data from
Autonomous Communities (AACC). This article
concludes that, both at the national and regional
levels, antibiotic consumption decreased from
1996 onwards, basically at the expense of reduc-
tions in the J1C wide-spectrum penicillin sub-
group. On the other hand, it also identiﬁes
important differences among AACC. There was
a global national antibiotic consumption of 20.4
DID in 2000, while the AACC with the highest
consumption were above 25 DID, even though
their consumption decreased along the observa-
tion period from 27 DID in 1985 [8].
Comparing these studies [4,7,8], it is very
important to underline the huge difference in the
values that each of them gave to the consump-
tion in 1997: 20.6 DHD according to Ruiz-
Bremo´n et al. and 32.4 DID according to Cars
et al. This discrepancy exempliﬁes the great
difﬁculty of obtaining data on consumption that
can be compared among countries. Another
recent article identiﬁes as the more important
methodological hurdles: the use of different
ATC ⁄DDD versions; differences in the assigna-
tion of DDD for the combinations of antibiotics;
the use of non-ofﬁcial or national DDD [9,10].
And last, but not least, in some instances
consumption data are derived only from pre-
scription databases within health systems,
whereas in others, total sales are obviously
higher since they include private and, in some
countries, over-the-counter prescriptions, thus
creating unavoidable discrepancies.
To further compound this scenario, we have to
face a second element which is the accuracy of the
estimation of resistance. Once such large differ-
ences in resistance have been observed within the
same country, it is quite naive to calculate a ‘mean’
prevalence of resistance for a given country. This
implies a considerable uncertainty regarding the
quantitative magnitude of resistance in a country,
if we can still use these terms. Perhaps the most
accurate estimation that we might perform is to
rate semiquantitatively, a country or region as
having a high, moderate, low, or very-low pre-
valence of resistance (on the basis of completely
arbitrary thresholds). The same can be said for
antibiotic consumption; rating countries as being
high, moderate, low, or very low consumers of
antibiotics is possibly the closest we might
approach reality. Even then, there are all the
limitations inherent in the ecological nature of the
study of such relationships [5].
CONSUMPTION OF
ANTIMICROBIALS AND SELECTION
OF RESISTANCE
The ﬁrst articles published on consumption of
antibiotics and resistance are no more than
15 years old [11–15]. These studies undertook
the assessment of the effects of the rise in
antibiotic consumption on the increase of preval-
ence of resistance to penicillin, erythromycin and
ciproﬂoxacin in S. pneumoniae and S. pyogenes in
the community over time.
Among these seminal articles are those of
Baquero et al. (1991) on penicillin use and resist-
ance in Europe; Kristinsson et al. on S. pneumoniae
[13]; and Se¨ppala et al. on S. pyogenes in Iceland and
Finland, respectively [11,12]. The last two studies
took advantage of havingwell-compiled databases
for their corresponding countries, these countries
having a low population predominantly concen-
trated in a few urban nuclei, with little trans-
border movement. Their results and conclusions
indicate a link between drug consumption and
penicillin and ⁄ or erythromycin resistance in these
respiratory pathogens, even though the inﬂuence
of local spread and spontaneous disappearance
of particular clones might explain in part the
observed trends, particularly for S. pyogenes. The
article by Chen et al. described a similar correla-
tion between quinolone consumption and S. pneu-
moniae resistance to ciproﬂoxacin in Canada [14].
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A number of articles provided the theoretical
framework for the hypothesis that the observation
of increases in the prevalence of resistance could
be explained by the use of antimicrobials and the
selective pressure that this poses to the bacterial
populations [16–19].
Other authors described similar observations in
countries with small populations such as Sweden,
Holland and Slovenia a few years later [20–24].
Shortly afterwards, increasing levels of resistance
were also conﬁrmed again in Finland and in
Germany [24,25], in the latter case with a different
demographical situation i.e., both the population
and number of trans-border movements are
considerably higher.
Variations in geographical clonal spread and
resistance rates
McCormick et al. concluded that the regional
differences observed in resistance of S. pneumoniae
within the USA were not due to a different
distribution of serotypes, more or less resistant,
but to differences in resistance rates within the
same serotype [26]. Therefore, in this analysis, the
regional differences were attributed to differences
in antibiotic consumption.
Regulation of antibiotic use and control of
antibiotic resistance
It was not until 1996 that a seminal article
concerning the possible regulation of antibiotic
use to control antibiotic resistance in Spain
(although it could be extended to other countries)
was published [27]. The document entitled‘Anti-
biotic Resistance in Spain: What Can Be Done?’ was
prepared in 1994 by an ad-hoc Task Force under
the auspices of the Spanish Ministry of Health.
The problem of the development of antibiotic
resistance in community-acquired bacterial path-
ogens in Spain and its relation to antibiotic use
and consumption were recognised as of both
national and international concern. This docu-
ment analysed the problem and provided general
recommendations for limiting the emergence,
evolution, and spread of resistant microorgan-
isms. Particular emphasis was given to systems
for surveillance of antibiotic resistance, the mon-
itoring of patterns of antibiotic use and consump-
tion, and strategies for inﬂuencing the producers
(the pharmaceutical industry), prescribers (physi-
cians and veterinarians), dispensers (pharma-
cists), and consumers (patients) of antibiotics. It
was also recognised that in order to control the
emergence and spread of antibiotic resistance
concerted efforts would be necessary on the part
of all social and scientiﬁc agencies involved in
health care.
Another important step was the publication in
1999 of the ﬁrst evidence that macrolide prescri-
bing and resistance patterns in S. pneumoniae
showed a correlation between increasing macro-
lide resistance and the increased use of newer,
long-acting macrolides in S. pneumoniae by analy-
sing the site prevalence of resistance and plotting
this against consumption of short and long-acting
macrolides, proving that this approach could be a
valid exploratory tool [28]. Other analyses from a
European perspective revealed that countries
with higher rates of antibiotic consumption were
those in which resistance was higher; and at the
same time, a number of possible sociobiological
determinants of antibiotic consumptiom were
recognised to be of potential importance. These
included genetic factors in human populations,
cultural factors and attitudes of patients towards
antibiotics, sociological factors or public health
factors, including the incidence of other infectious
diseases in human populations [29]. The estima-
tion of the importance of human genetic factors in
the prevalence of pneumococcal colonisation and
disease represents a new possibility for research.
The determinants of both innate and humoral
immunity to S. pneumoniae are becoming known;
thus detection of regional differences in human
genetic polymorphisms in molecules such as Toll-
like receptors, speciﬁc C-type lectins, or nucleo-
tide-binding oligomerisation domain proteins is
awaited in order to make progress in understand-
ing the complex epidemiological landscape in
which antibiotic resistance is evolving [30–32].
The Willow (SAUCE) Project
In linewith the spirit of the Task Force document to
curtail resistance, an ambitious cooperative project
between the pharmaceutical industry, on the part
of the then SmithKline Beecham S.A., now Glaxo-
SmithKline S.A., a network of hospitals growing
over time; (14 in 1996–97, 17 in 1998–99 and 24 in
2001–02) and the National Center of Microbiology
of the Institute for Health Carlos III, part of the
Ministry of Health, was intiated with the aim of
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gathering a large collection of well-characterised
respiratory isolates of the key bacterial species in
which resistance was posing a problem, namely,
S. pneumoniae, S. pyogenes and H. inﬂuenzae. The
Spanish word for willow-tree is ‘sauce’, which was
used as the acronym for the Project (SAUCE,
Susceptibility to the Antibiotics Used in the Com-
munity in ‘Espan˜a’). From 1996 to 2002 there have
been three reports from this joint initiative covering
the periods 1996–97, 1998–99 and 2001–02, and a
fourth is upcoming for 2006–07. This project has
enabled us to have an accurate idea of what is
happening in Spain with respect to resistance in
each targeted species [33–38], and to associate total
or local resistance prevalence with antibiotic con-
sumption in different ways in order to explore the
speciﬁc relationship between resistance and drug
use. The importance of creating such a collection is
further demonstrated by the opportunity to study
in depth isolates with worrying resistant pheno-
types in order to explore explanatory mechanisms
of resistance and the importance of clonal spread
[39–43].
b-lactam and macrolide use and selection of
resistance in the Willow (SAUCE) Project
Based on data from the Willow (SAUCE) Project,
Granizo et al. identiﬁed a clear historical trend in
the temporal evolution of resistance to penicillin
and erythromycin in S. pneumoniae between 1987
and 1997 and studied the potential relationship
that resistance could have to the consumption of
b-lactams and macrolides, and made distinctions
within these families [44]. It was suggested that
overuse of certain speciﬁc antibiotics, namely oral
cephalosporins and long half-life macrolides, was
likely to be related to the increase in drug-
resistant S. pneumoniae isolates. Using basically
the same methodology, a similar analysis was also
undertaken for S. pyogenes and its resistance to
erythromycin in the context of the increasing use
of macrolides, mostly those of longer half-life [45].
The pharmacokinetic bases for higher selective
power of long-acting macrolides were previously
examined [28].
Using retrospective data concerning resistance
was difﬁcult because selection of representative
articles (when they existed) was necessarily
biased, and data on antibiotic consumption were
very difﬁcult to manage since they were not
entered into electronic databases. One possible
way to overcome these problems could be a
geographical approach and such a strategy was
used in the Willow (SAUCE) Project. If different
time-points corresponded with different estimates
of resistance and consumption, the same might be
applied to different regions where heterogeneity
could take over the directional and changing
nature of time. This approach, taking advantage
of large administrative units for studies of pop-
ulation health within a country has been success-
fully used, in the ﬁeld of sociology. Given the
exploratory nature of the method, no causal
hypotheses can be proposed at the outset [46].
With these premises in mind, the approach
proved to be useful [6,47], even to explore factors
associated with different antibiotic use within
provinces [5]. For instance, in the case of S.
pneumoniae macrolides appeared to be more
important drivers for local differences in both
erythromycin and penicillin resistance than b-
lactams. Once-a-day macrolides were key in local
erythromycin resistance variations, and cephalo-
sporins were more important drivers of penicillin-
resistance than aminopenicillins [6]. However, in
the case of S. pyogenes and its resistance to
erythromycin, the subgroups of macrolides had
an additive rather than a differential selective
effect, being the main factor contributing to the
total amount of macrolides used above a critical
threshold of consumption [47]. Other approaches,
e.g., the autoregressive integrated model aver-
age (ARIMA) temporal series which are less
intuitive, seem more complicated for open com-
munities, although they have proved to be useful
for hospital epidemics [48–53].
More recently, an apparent decrease in penicil-
lin resistance in S. pneumoniae with an increase in
erythromycin resistance, has been reported
[38,54]. In one of these studies, the Spanish branch
of the European Antimicrobial Resistance Sur-
veillance System (EARSS) contributed data dur-
ing a period (2002–03) not covered by the Willow
Study. A clear trend indicating a decrease in
b-lactam resistance in invasive S. pneumoniae was
detected, particularly in children (from 60 to 41%,
p = 0.002), that might be attributed, at least in
part, to a signiﬁcant increase in the population
that has received the heptavalent conjugated
pneumococcal vaccine. During these years a
decline in broad-spectrum penicillin and cepha-
losporin use was detected, even though the use of
amoxicillin-clavulanate increased by 17.5%. The
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continuous rise in macrolide resistance in inva-
sive S. pneumoniae was also conﬁrmed by the
Spanish branch of the EARSS [55].
Fluoroquinolone consumption and resistance in
the Willow (SAUCE) Project
The consumption of quinolones has increased
worldwide, which could inﬂuence the prevalence
of resistance in several pathogens. Unfortunately,
Spain has a high prevalence of resistance and
large antibiotic consumption. In invasive E. coli
hospital isolates resistance to ciproﬂoxacin was
19.3% in a recent Spanish study [56]. Up to 23%
of the E. coli isolates in the community are already
resistant to ciproﬂoxacin [57], as are c. 5–6% of
S. pneumoniae isolates (MIC ‡ 4 mg ⁄L) and 3.5%
of S. pyogenes [38,58]. The Spanish branch of
the EARSS Group has recently documented
an increase in invasive pneumococcal isolates
with resistance to ciproﬂoxacin (0.4% in 2001
vs. 3.9% in 2003 for strains of MIC > 2 mg ⁄L)
coincident with a 27% increase in ﬂuoroquino-
lone prescriptions (data obtained from the ofﬁcial
prescription database of the Ministry of Health),
particularly involving the so called respiratory
quinolones levoﬂoxacin and moxiﬂoxacin [54].
The data on ﬂuoroquinolone resistance S. pneu-
moniae obtained in the Willow (SAUCE) Project
were analysed from both temporal and geograph-
ical perspectives, and compared with IMS local
data on ﬂuoroquinolone consumption.
Temporal evolution of quinolone consumption
in Spain: 1997–2001
Total wholesaler sales to the retail market by unit
and presentation per year made by IMS Health
Spain. The DDD were calculated and adjusted by
population and expressed in 1000 inhabitants per
day (DDD ⁄ 1000 ⁄day = DID) following the 2002
WHO Collaborating Centre for Drug Statistics
Methodology recommendations [59], using the
DDDs software calculator of the Danish Staten
Serum Institute [60]. Ofﬁcial demography data
were retrieved from the web page of the Spanish
Institute for Statistics (http://www.ine.es).
The consumption of quinolones in 1997 was
2.49 DID, i.e., 12% higher than the ofﬁcial data
that quoted 2.22 DID for the same year [61]. From
then on, the consumption of quinolones increased
by 15.6% in the next four years (1997–2001) (c. 4%
per year). From 1999, the so called respiratory
quinolones (levoﬂoxacin and moxiﬂoxacin) have
experienced the highest increases (119% and
37%, respectively). Ciproﬂoxacin has increased
10% from 1997 (2.5% ⁄ year). The remaining mar-
keted quinolones currently are of only marginal
importance. Although neither grepaﬂoxacin nor
trovaﬂoxacin are marketed any longer, their brief
existence accounted for 6.3% of total quinolone
sales in 1999 (Fig. 1).
As mentioned, Oteo et al. [54], also making use
of the Spanish Ministry of Health prescription
database, obtained a consumption estimate widely
different from what we have calculated, although,
interestingly, their estimate does not coincide with
that of Ruiz-Bremon et al. [8] In 1997 Ruiz-Bremon
offered an estimate of 2.22 DID consumption
whereas Oteo’s estimation in 1998 was 1.96 DID,
almost 12% less. So, it is understandable that our
estimation for 1998 was 2.52 DID, 28% higher than
Oteo’s. This discrepancy decreased to 22% in 2001
(2.88 vs. 2.36). In 2002, the consumption surpassed
the threshold of 3 DID, which is also in line with
the observed annual rate of increase of 5%
between 2000 and 2001. Discrepancies between
ofﬁcial consumption ﬁgures and IMS data should
relate to private or over-the-counter consumption.
Our data indicate that the total consumption of
quinolones has increased by 15.6% during the
observation period of 5 years, basically due to the
arrival of the respiratory quinolones levoﬂoxacin
and moxiﬂoxacin whose consumption was super-
imposed upon the already important use of
ciproﬂoxacin and norﬂoxacin for urinary indica-
tions. The consumption of ciproﬂoxacin, constitu-
ting 45% of the total group consumed during this
period, has also increased by 10%, despite a very
high prevalence of resistance in E. coli, already
c. 10–20% in 1996.
Temporal evolution of ciproﬂoxacin resistance
in S. pneumoniae in Spain: ﬂux and reﬂux
Based on data from the SAUCE database
[34,36,38], resistance to ciproﬂoxacin (MIC
Table 1. Temporal evolution of ciproﬂoxacin resistance in
Spain
CMI Ciproﬂoxacin 1997 1999 2002
‡ 2 mg ⁄L 20.9% 35.0% 22.3%
‡ 4 mg ⁄L 5.3% 7.1% 4.6%
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‡ 4 mg ⁄L) increased to 7.1% in 1999 from an
initial prevalence of 5.3% in 1996–97. Accord-
ingly, with such rates of increase a prevalence
that c. 9% was expected for 2002. Surprisingly,
what we found was a reversal to the original
starting point, with a current 4.6% resistance
(Table 1). Oteo et al. found a resistance rate of
2.1% for invasive isolates. A similar trend was
observed when we studied the prevalence of
S. pneumoniae with an MIC ‡ 2 mg ⁄L. On this
occasion, from the initial 20.9% we ended up
with the current 22.3% going through the peak
of 35% in 1997. Fig. 2 provides a graphical
depiction of these data.
Geographical variation in ﬂuoroquinolone
consumption and resistance to ciproﬂoxacin in
S. pneumoniae in Spain: the emergence of an
inverse correlation
The data concerning consumption of quinolones
(DDD ⁄ 1000 ⁄day) in each of the Spanish provinces
studied between August 2001 and October 2002,
compared with the provinces in which the
SAUCE-3 study was performed, is presented in
Table 2. The mean monthly quinolone consump-
tion during this observation period was calcula-
ted and the corresponding prevalence of
resistance for ciproﬂoxacin and levoﬂoxacin is
also provided. A simple linear regression was
performed, considering the estimate of ciproﬂ-
oxacin nonsusceptibility by province (‡ 2 ) as the
dependent variable and the consumption as the
independent term. Values whose residuals were ±
2 standard deviations were removed (Vizcaya,
Zaragoza and Valladolid). Contrary to our expec-
tations, but consistent with the overall prevalence
data, a statistically signiﬁcant inverse correlation
(p = 0.011) and an acceptable R-value of 0.6 were
found (Fig. 3).
Inverse correlation between ﬂuoroquinolone
consumption and resistance in S. pneumoniae in
Spain
During the observational period of the Willow
(SAUCE) Project, we did not ﬁnd a continuous
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linear increase in the resistance rates to ciproﬂ-
oxacin in S. pneumoniae. Resistance rates went
from 5.3 to 7.1%, and then decreased to 4.7% in
2002, despite a continuous increase in ﬂuoroqu-
inolone consumption. To our surprise, and con-
ﬁrming our observations overtime, we have
found, after removing outlier values, an inverse
correlation between quinolone consumption and
nonsusceptibility to ciproﬂoxacin by province.
This seems to argue against what, until now, has
been consistently reported by many authors
(including ourselves), that is direct and linear
correlation between consumption and resistance.
We can examine a number of hypotheses in
order to explain this puzzling observation. First,
the inﬂuence of the heterogeneity of the different
drugs within the ﬂuoroquinolone group of anti-
microbials was considered. The replacement of
ciproﬂoxacin by the newer ‘respiratory ﬂuoroqu-
inolones’ with higher activity against S. pneumo-
niae might have discontinued selection towards
higher rates of resistance. More active ﬂuoroqu-
inolones could prevent selection of resistance [62].
In this sense, there is pharmacodynamic evidence
of an inverse relationship between quinolone
concentration and the frequency of selection of
resistant mutants in vitro and in vivo [63,64].
Second, the inﬂuence of the total amount of
ﬂuoroquinolones in the selective environment,
surpassing a putative threshold of adaptability in
S. pneumoniae populations was considered. Would
it be possible to hypothesise that given a sufﬁ-
ciently high level of antibiotic pressure, the
biological cost of resistance is so high that it is
no longer worth while? Once that resistance has
been optimised for a given intensity of antibiotic
selection, might further increases of consumption
have a paradoxical effect by reducing the global
prevalence of resistance in the bacterial popula-
tion?
Third, the inﬂuence of the nonquinolone anti-
biotics in the selective environment on the bio-
logical costs of ﬂuoroquinolone resistance was
considered. The biological costs associated with
mutations leading to ﬂuoroquinolone-resistance
have not been well evaluated in S. pneumoniae. In
other organisms, particularly in Gram-negatives,
cumulative mutations leading to higher levels of
resistance reduce bacterial ﬁtness [65–67]. In
S. pneumoniae, early observations indicate that
Table 2. Quinolone consumption
and resistance to ciproﬂoxacin in
Streptococcus pneumoniae by province
in Spain
Province
I + R%
Cip
I + R%
Lev
HighR%
Cip
HighR%
Lev
Quinolone
DDD ⁄ 1000 h ⁄day
Vizcaya 9.1 4.5 4.5 0.0 1.703
Cantabria 18 1.3 3.3 1.3 2.274
Pontevedra 17.4 0.0 2.2 0.0 3.523
Granada 18.9 5.7 9.4 5.7 3.184
Barcelona 24.1 1.0 3.7 0.6 2.043
Salamanca 11.6 0.0 4.7 0.0 3.675
La Corun˜a 20.8 2.1 7.3 2.1 2.405
Zaragoza 13.9 0.0 2.8 0.0 2.012
Guipu´zcoa 27.5 2.5 4.8 1.3 1.492
Valencia 19.1 0.0 2.4 0.0 3.026
Ca´diz 19.4 2.8 11.1 2.8 3.260
Madrid 21.5 1.7 4.1 1.7 2.569
Gran Canaria 20.9 0.0 3.6 0.0 3.516
Ciudad Real 21.1 5.3 5.3 2.6 3.498
Co´rdoba 17 0.0 4.3 0.0 3.224
Baleares 23.8 0.0 2.9 0.0 3.137
Valladolid 28.6 6.3 14.3 4.8 2.809
Murcia 15.1 1.9 4.7 1.9 3.076
Sevilla 18.8 0.0 2.1 0.0 3.039
Ma´laga 21.9 3.1 9.4 1.6 3.455
0 1 2
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Fig. 3. Inverse correlation between quinolone consump-
tion and resistance to ciproﬂoxacin by province in Spain.
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ciproﬂoxacin resistance was associated with
increased susceptibility to b-lactams [68]. The
hypothesis is that the cost of ﬂuoroquinolone
resistance could be expressed preferentially under
challenge with other unrelated antibiotics, such as
b-lactams. In environments in which the ﬂuoro-
quinolone-resistant mutants could emerge among
penicillin-intermediate populations, penicillins,
especially at high dosage might limit the selection
of ﬂuoroquinolone resistance. If b-lactams are
sparingly used, such an effect is also limited and
ﬂuoroquinolone resistance could spread more
easily. Moreover, local diversiﬁcation in the use
of antibiotics – once a given intensity of use for all
of them is surpassed ) should also reduce the
selection of ﬂuoroquinolone resistant mutants.
And fourth, the inﬂuence of changes in tem-
poral or spatial prevalence of particular clones
was considered. Although in Spain ciproﬂoxacin
resistant pneumococcal isolates are polyclonal,
the observation that 30% of these strains belonged
to one or two international, epidemic, multidrug
resistance clones, raised serious concerns of poss-
ible future spread [39]. It has been shown that
even in the absence of increasing antibiotic use,
clonal spread and herd immunity are important
factors to be considered in the evaluation of the
effects of intervention [69]. The widespread use of
the heptavalent conjugated vaccine since 2001 has
reduced the frequency of a number of former
clones in the Spanish population. The predomin-
ant multiresistant (multiselectable) clones were
those with a higher possibility of acquiring
ﬂuoroquinolone resistance. Indeed, most ciproﬂ-
oxacin-resistant strains occur in penicillin-resist-
ant clones [70]. These being the clones targeted by
vaccination, ﬂuoroquinolone resistance should
follow the decrease of penicillin-resistance. Even-
tually, the decrease in the resistance rates in S.
pneumoniae to ciproﬂoxacin observed between
1999 and 2002 could be explained, at least in part,
by the introduction of antipneumococcal vaccine
in Spain in 2001.
As we have already reported for total antibiot-
ics, b-lactams and macrolides [5], we have found
marked differences in the degree of quinolone
consumption among the studied provinces. Con-
sumption can be more than twice as high as
others in certain provinces. The paradox is that
those provinces with higher consumption of
quinolones have a lower prevalence of resistance
in S. pneumoniae to ciproﬂoxacin. In our second
hypothesis, we speculate that once a given
threshold of quinolone consumption has maxim-
ised a prevalence of resistance of c. 7% (and 35%
for a breakpoint of ‡ 2 mg ⁄L) further increases in
consumption led by the respiratory quinolones
have broken the balance and set up a new set
point of equilibrium to the right of an inverse
quadratic curve. Our third hypothesis might also
apply here. In general, those areas with low
ﬂuoroquinolone consumption are those in which
other antibiotics are also less frequently used. In
some of them (as in the Basque Country) the high
local prevalence of particular clones,
eg., Spain14)5, made these organisms particularly
prone (for probabilistic reasons) to acquiring
ﬂuoroquinolone resistance [71]. With low rates
of consumption of other antimicrobials, the cost of
ﬂuoroquinolone resistance might not have been
expressed, or the ‘diversiﬁcation’ in drug use has
not reached the consumption threshold necessary
to limit the spread of the resistant clones. Inter-
estingly, a similar phenomenon, higher E. coli
ﬂuoroquinolone resistance and lower ﬂuoro-
quinolone consumption than in other Spanish
regions, was also found in the Basque country for
treatment of E. coli involved in intra-abdominal
infections (data not shown).
The correlation between antibiotic consump-
tion and resistance in S. pneumoniae is based on a
complex network of biological and environmental
interactions, and it is the role of microbiologists,
epidemiologists, and mathematical modellers, to
identify the key factors governing this multifac-
torial phenomenon, in order to understand it and
to design the most appropriate interventions
accordingly.
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